OncoZenge AB Stock

Equities

ONCOZ

SE0015504097

Pharmaceuticals

Market Closed - Nasdaq Stockholm 10:14:26 2024-05-06 am EDT 5-day change 1st Jan Change
3.945 SEK +2.73% Intraday chart for OncoZenge AB +7.49% +27.67%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * - Sales 2025 * - Capitalization 46.21M 499M
Net income 2024 * -8M -86.37M Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * 3M 32.39M Net cash position 2025 * 3M 32.39M EV / Sales 2025 * -
P/E ratio 2024 *
-5.8 x
P/E ratio 2025 *
-
Employees 2
Yield 2024 *
-
Yield 2025 *
-
Free-Float 40.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.73%
1 week+7.49%
Current month+6.05%
1 month+8.53%
3 months-20.78%
6 months+51.73%
Current year+27.67%
More quotes
1 week
3.62
Extreme 3.62
4.38
1 month
3.48
Extreme 3.475
4.50
Current year
2.80
Extreme 2.8
7.96
1 year
1.60
Extreme 1.6
10.10
3 years
1.60
Extreme 1.6
15.00
5 years
1.60
Extreme 1.6
17.60
10 years
1.60
Extreme 1.6
17.60
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-09-12
Director of Finance/CFO 68 23-10-11
Chief Tech/Sci/R&D Officer 72 21-04-30
Members of the board TitleAgeSince
Director/Board Member 38 23-09-08
More insiders
Date Price Change Volume
24-05-06 3.945 +2.73% 48,293
24-05-03 3.84 -1.41% 12,097
24-05-02 3.895 +4.70% 25,754
24-04-30 3.72 +1.36% 24,305

Delayed Quote Nasdaq Stockholm, May 06, 2024 at 10:14 am EDT

More quotes
OncoZenge AB is a Sweden-based pharmaceutical company, that develops products for cancer supportive care. OncoZenge's vision is to improve the quality of life for patients with severe oral pain, for example caused by radiotherapy or chemotherapy in the treatment of cancer. The Company works on the introduction of its project BupiZenge. Its strategic and operational work focuses on the development of BupiZenge, which is a formulation of bupivacaine in the form of a lozenge. BupiZenge meets a need for pain relief in the mouth and throat, for example associated with oral mucositis, a serious complication after radiation or other cancer treatment. Preparations for registration establishment clinical studies are ongoing.
Calendar
More about the company

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW